IL-33: A Potential Therapeutic Target in Autoimmune Diseases

Interleukin 33 (IL-33) is a newly described member of the IL-1 superfamily of cytokines. Through activation of the ST2 receptor, which is widely expressed particularly by helper T 2 cells and mast cells, IL-33 is involved in T-cell–mediated immune responses. Many previous studies have demonstrated t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Investigative Medicine 2012-12, Vol.60 (8), p.1151-1156
Main Authors: Wang, Song, Ding, Lei, Liu, Shan-Shan, Wang, Chao, Leng, Rui-Xue, Chen, Gui-Mei, Fan, Yin-Guang, Pan, Hai-Feng, Ye, Dong-Qing
Format: Article
Language:English
Subjects:
Animals
Autoimmune Diseases - drug therapy
Autoimmune Diseases - metabolism
Drug Delivery Systems - methods
Drug Delivery Systems - trends
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - metabolism
Interleukin-33
Interleukins - antagonists & inhibitors
Interleukins - metabolism
Signal Transduction - drug effects
Signal Transduction - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin 33 (IL-33) is a newly described member of the IL-1 superfamily of cytokines. Through activation of the ST2 receptor, which is widely expressed particularly by helper T 2 cells and mast cells, IL-33 is involved in T-cell–mediated immune responses. Many previous studies have demonstrated that IL-33 may have a pleiotropic function in different diseases, and it could represent a novel target for the treatment of a range of diseases. Recent works have explored the role of IL-33 in chronic autoimmune diseases, such as systemic sclerosis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus. These results indicate that IL-33 may contribute to the pathogenesis of chronic autoimmune diseases. Hence, in this review, we discuss the biological features of IL-33 and summarize recent advances on the role of IL-33 in the pathogenesis and treatment of autoimmune diseases.
ISSN:1081-5589
1708-8267
DOI:10.2310/JIM.0b013e31826d8fcb